Afternoon, everyone. My name is Jeffrey Aronin, and I am the Chairman of the Harmony Biosciences Board of Directors. It is my privilege to welcome you to our 2026 Annual Meeting of Stockholders. At this time, I would like to introduce the President and CEO of Harmony Biosciences, Dr. Jeffrey Dayno, who will serve as the Chair of the Annual Meeting of Stockholders. Thank you, Jeff. It is now 1:00 P.M. Eastern Time, and as Chair of this Annual Meeting of Stockholders, I would like to formally call the meeting to order. This meeting is held pursuant to the company's bylaws and the written notice sent to all stockholders of record as of March 17, 2026. The agenda for the meeting has been posted on the virtual meeting website. Our board of directors fixed March 17, 2026 as the record date for determining stockholder entities to vote at this meeting. We have the proof required by Delaware law and our bylaws that the notice of annual meeting, the proxy statement, the proxy card, and annual report for the fiscal year 2025 were mailed to stockholders commencing on April 3, 2026. The affidavit is available if any stockholder wishes to examine it and will be filed with the minutes of this meeting. The stockholder list shows that as of the record date, there were 57,867,389 shares of our common stock outstanding and entitled to vote at the meeting. The list of stockholders and the number of shares held by each such stockholder as of the record date is available on the virtual meeting website for any stockholder wishing to inspect it and is also available upon r equest. The board of directors appointed Broadridge Financial Solutions to act as Inspector of Election at this meeting. The Inspector of Election has been sworn in, and I have his oath, which will be included in the minutes of this meeting. I have been advised by our Inspector of Election that immediately prior to these proceedings, that the holders of a majority in voting power of all issued and outstanding shares of common stock entitled to vote are present or represented by proxy at today's meeting. With confirmation that a quorum is present, the business of the meeting may proceed. In addition to myself, we also have a number of company officers here with us. Joining me today via telephone are the following, Christian Ulrich, General Counsel, Dr. Kumar Budur, Chief Medical and Scientific Officer, Andrew Serafin, Chief Strategy Officer, Glenn Reicin, Chief Financial Officer, Peter Anastasiou, Chief Operating Officer, Cate McCanless, Chief Corporate Affairs Officer, and Adam Zaeske, Chief Commercial Officer. Further, in addition to the Chairman of our Board of Directors, Jeffrey Aronin, and myself, various other members of our Board of Directors have joined us today via telephone. We also have representatives from Deloitte & Touche LLP, our independent registered public accounting firm, in attendance who are prepared to answer any questions that stockholders may have. Christian Ulrich, our General Counsel, will serve as Secretary of the meeting and record the proceedings. The rules of conduct have been posted on the virtual meeting website. These rules apply to the meeting, our business presentation, and our Q&A session. In order to conduct an orderly meeting, we ask that all participants abide by these rules. Please note that no one attending the meeting via webcast or telephone is permitted to use any audio or video recording device. When the report of the Inspector of Election is complete, we will announce the preliminary results. If you have not already voted, please do so now. The polls open today, May 14th, at 1:00 P.M. Eastern Time for voting on all matters before the meeting. If you have provided your proxy card, your shares will be voted in accordance with your instructions. If you have not already voted and wish to vote, or if you wish to change your vote, the polls will remain open until we announce the closing of the polls, and you may vote by clicking on the Voting button on the virtual meeting website and following the instructions there. Stockholders who have sent in proxies or voted via telephone or Internet, and do not want to change their vote do not need to take any further action. Now, moving on to the first formal item on our agenda. The first item of business presented for a vote is the nomination of candidates for election of four Class 3 directors to the Harmony Biosciences Board of Directors. The candidates for director who have been nominated to serve as directors by Harmony Biosciences Nominating and Corporate Governance Committee and Board of Directors are Gino Germano, Troy Ignelzi, Ron Philip, and Andreas Wicki. The proxy statement made available to you describes each nominee's experience and qualifications. No other nominations complying with the nomination procedures in the company's bylaws have been received. The nominations are closed. Pursuant to the company's certificate of incorporation and bylaws, the company's board of directors is divided into three classes, with each class being elected every three years. At this meeting, Gino Germano, Troy Ignelzi, Ron Philip, and Andreas Wicki have been nominated as Class 3 directors of the company to serve until the 2029 annual meeting of stockholders, or until each nominee's respective successors have been duly elected and qualified. The board of directors has unanimously recommended that the stockholders vote for each of Gino Germano, Troy Ignelzi, Ron Philip, and Andreas Wicki as directors of Harmony Biosciences to serve and hold office until the 2029 annual meeting of stockholders and until each nominee's respective successors have been duly elected and qualified. The second item of business presented for a vote is to ratify the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the year ending December 31st, 2026. The proxy statement made available to you describes their appointment and scope of work for Harmony Biosciences. The board of directors has unanimously recommended that the stockholders vote for the ratification of Deloitte & Touche LLP as Harmony Biosciences' independent registered public accounting firm for 2026. The third item of business presented for a vote is to approve on a non-binding advisory basis the compensation of our named executive officers pursuant to the SEC's compensation disclosure or Say-on-Pay rules. The board of directors has unanimously recommended that the stockholders vote for the approval on a non-binding advisory basis of the compensation of our named executive officers. I will now pause for a short moment to give stockholders a chance to finish voting. Time is now 1:09 P.M. Eastern Time, and I now declare the polls closed, and the inspector of election will tabulate the votes. I understand that the votes have been counted and the preliminary report of the inspector of election has been delivered to Harmony Biosciences. Any ballots collected before the polls close, but not reflected in the preliminary report, will be reflected in the final report of the inspector of election, which will be affixed to the minutes of the meeting. Following this meeting, the inspector of election will prepare the certificate of the inspector for the company once all votes are tallied, and the results will be detailed in a current report on Form 8-K, which we will file with the Securities and Exchange Commission. Christian, will you please announce the preliminary results of the stockholders' vote on the three proposals at this time? The preliminary report of the inspector of election indicates that a sufficient number of votes were voted for each proposal, such that each of Gino Germano, Troy Ignelzi, Ron Philip, and Andreas Wicki have been duly elected as Class 3 directors of the company to serve until the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified. The appointment of Deloitte & Touche LLP as Harmony Biosciences independent registered public accounting firm for the year ending December 31st, 2026, has been approved and ratified. The compensation of our named executive officers has been approved on a non-binding advisory basis. Thank you, Christian. That concludes today's formal business. As there are no other matters properly scheduled to come before the meeting, this meeting is now adjourned. I hereby request that the final report of the inspector of election be filed with the minutes of this meeting. Thank you for your participation. At this time, we will now answer appropriate questions from stockholders. We can begin with those questions that we received. We will then take stockholders' questions that are being entered today on the virtual meeting website. Please note that in accordance with the rules of conduct, we will attempt to answer as many questions as time allows, but only questions that are germane to the meeting and submitted in accordance with the rules of conduct for the meeting will be addressed. That will conclude our question- and- answer session. Thank you everyone for your participation. The meeting has now concluded. Thank you for joining, and have a pleasant day.